Financial Performance - Kodiak Sciences reported a net loss of $43.9 million, or $0.84 per share, for Q3 2024, an improvement from a net loss of $50.0 million, or $0.95 per share, in Q3 2023[6]. - Total operating expenses for the three months ended September 30, 2024, were $46.6 million, a decrease from $54.5 million in the same period in 2023[14]. - The net loss for the three months ended September 30, 2024, was $43.9 million, compared to a net loss of $50.0 million in the same period in 2023[14]. - Cash and cash equivalents decreased to $197,864,000 from $285,507,000, a decline of approximately 30.6%[15]. - Working capital decreased to $178,433,000 from $247,580,000, representing a decrease of about 28%[15]. - Total assets decreased to $372,669,000 from $479,372,000, a reduction of approximately 22.2%[15]. - Accumulated deficit increased to $(1,284,633,000) from $(1,152,531,000), reflecting a worsening of about 11.5%[15]. - Total stockholders' equity decreased to $185,370,000 from $265,781,000, a decline of approximately 30.2%[15]. Research and Development - Research and development expenses decreased to $31.9 million in Q3 2024 from $36.2 million in Q3 2023, primarily due to reduced manufacturing and completed clinical activities[7]. - General and administrative expenses were $14.8 million in Q3 2024, down from $18.3 million in Q3 2023[8]. - The phase 3 GLOW2 study for tarcocimab in diabetic retinopathy is enrolling patients, aiming for a topline data readout in 48 weeks[1]. - The phase 3 DAYBREAK study for wet AMD is also enrolling patients, with a focus on assessing the 6-month durability of tarcocimab[3]. - Tarcocimab demonstrated an ocular half-life of 20 days, which is 3 times longer than faricimab and 2-3 times longer than aflibercept[1]. - The KSI-101 clinical program is currently in the APEX study, targeting macular edema secondary to inflammation, with early data showing meaningful clinical responses[1]. - Kodiak is advancing two preclinical programs from its ABCD Platform, targeting glaucoma and dry AMD, with the goal of creating therapies with dual mechanisms of action[4]. - The company aims to file a single Biologics License Application for three diseases based on data from five successful phase 3 studies if GLOW2 and DAYBREAK are successful[1]. - Tarcocimab has completed three successful Phase 3 pivotal clinical studies, achieving 100% treatment success in the GLOW1 study for diabetic retinopathy with extended 6-month dosing[9]. - In the BEACON study, nearly 50% of patients treated with tarcocimab did not require any treatment in the second 6 months while achieving similar vision outcomes as the aflibercept group[9]. - Kodiak is currently conducting two Phase 3 clinical trials for tarcocimab: GLOW2 for diabetic retinopathy and DAYBREAK for wet AMD, both actively enrolling patients[9]. - KSI-501, a bispecific antibody, is in a Phase 3 study (DAYBREAK) evaluating its efficacy against aflibercept, with a primary endpoint of non-inferiority in visual acuity[10]. - KSI-101 is in a Phase 1b study (APEX) targeting retinal inflammatory diseases, with plans to progress into dual Phase 2b/3 studies[11]. Strategic Initiatives - Kodiak plans to file a single Biologics License Application (BLA) for three diseases based on data from five successful Phase 3 studies with tarcocimab[13]. - Kodiak's ABCD Platform aims to enhance drug delivery by embedding small molecules into its biopolymer backbone, expanding therapeutic applications[12]. - Kodiak's weighted-average shares outstanding for computing net loss per common share were 52,616,183 for the three months ended September 30, 2024[14].

Core Insights - Kodiak Sciences Inc. reported significant advancements in its clinical programs and financial results for Q3 2024, highlighting the ongoing development of its investigational therapies, particularly tarcocimab, KSI-501, and KSI-101 [1][17]. Clinical Developments - The company hosted an Investor R&D Day, presenting new clinical data showing that tarcocimab has an ocular half-life of 20 days, which is three times longer than faricimab and two to three times longer than aflibercept [2][4]. - The Phase 3 GLOW2 study for diabetic retinopathy is currently enrolling patients, aiming to replicate the success of the previous GLOW1 study with all patients on a 6-month dosing schedule [2][5][7]. - The DAYBREAK study is also enrolling patients for wet age-related macular degeneration (AMD), focusing on longer durability and better efficacy with KSI-501 [2][8][11]. - KSI-101 is being evaluated in the APEX study for macular edema secondary to inflammation, with early data showing promising clinical responses [3][13]. Financial Performance - Kodiak ended Q3 2024 with $197.9 million in cash and cash equivalents, which is expected to support operations into 2026 [17]. - The net loss for Q3 2024 was $43.9 million, or $0.84 per share, an improvement from a net loss of $50.0 million, or $0.95 per share, in Q3 2023 [18][37]. - Research and development expenses decreased to $31.9 million in Q3 2024 from $36.2 million in Q3 2023, primarily due to reduced manufacturing and clinical activities for completed trials [18][37]. Market Context - The retinal vascular diseases anti-VEGF market presents significant opportunities for therapies with high efficacy and durability, which Kodiak aims to address with its enhanced formulations of tarcocimab and KSI-501 [2][4]. - The company is also targeting the unmet needs in the macular edema and inflammation market, where over 100,000 patients in the U.S. currently lack approved therapies beyond steroids [2][3]. Pipeline Expansion - Kodiak is advancing its ABCD Platform to develop new therapies for glaucoma and dry AMD, aiming to create intravitreal injections with dual mechanisms of action for better efficacy and extended durability [14][15][16]. - The company is actively enrolling patients in its clinical studies for KSI-501 and KSI-101, with plans to progress into pivotal studies based on the outcomes of the ongoing trials [27][32].

Core Insights - Kodiak Sciences Inc. is focused on developing transformative therapeutics for retinal diseases and will present at upcoming investor conferences [1][2][3] Company Overview - Kodiak Sciences Inc. is a biopharmaceutical company dedicated to researching, developing, and commercializing therapeutics for retinal diseases, utilizing its proprietary ABCD Platform™ for drug development [3][7] - The company is advancing a portfolio of three clinical programs, with two in late-stage development and one expected to progress rapidly into pivotal studies [3] Investigational Medicines - Tarcocimab, Kodiak's lead investigational medicine, is an anti-VEGF antibody biopolymer conjugate being studied in two Phase 3 trials for diabetic retinopathy and wet AMD [4] - KSI-501 is a first-in-class bispecific antibody biopolymer conjugate targeting IL-6 and VEGF, currently in a Phase 3 study for wet AMD [5] - KSI-101 is a novel bispecific protein for retinal inflammatory diseases, with a Phase 1b study ongoing and plans for further Phase 2b/3 studies [6] Technology Platform - The ABCD Platform enables the development of high drug-antibody-ratio medicines by embedding small molecules into a proprietary biopolymer backbone, allowing for targeted and tailored therapeutic applications [7]

PALO ALTO, Calif., Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. Presentation and Panel details are below: Presentation Title: Update on Antibody Biopolymer Conjugates: Optimizing Immediacy and Durabilit ...

Kodiak Sciences (KOD) is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic and high-prevalence retinal diseases, which are the major causes of blindness. The company's proprietary antibody biopolymer conjugate platform is designed to maintain potent and effective drug levels in ocular tissues for longer periods than the currently marketed biologic medicines for treating retinal diseases. The company currently has no marketed drug in its portfolio. Kodiak is ...

A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD) . Shares have lost about 8.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Kodiak Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Kodiak Q2 Loss Narrower Than Expected ...

Kodiak Sciences Inc. (KOD) incurred a loss of 86 cents per share in the second quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 87 cents. The company had incurred a loss of $1.53 per share in the year-ago quarter. The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues. Quarter in Detail Research and development expenses were $32.5 million in the reported quarter, down 51.5% year over year. The decrease was mai ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State ...

Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results Palo Alto, CA — August 14, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy ...

PALO ALTO, Calif., Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy continues to enroll. The Phase 3 DAYBREAK study of tarcocimab and KSI-501 is now actively enr ...